Denali Therapeutics sells rare paediatric PRV for $195m
Denali Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million, with the deal subject to standard antitrust clearance under the Hart-Scott-Rodino Act.
The FDA issued the voucher to the South San Francisco company in March 2026 following accelerated approval of AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement therapy for Hunter syndrome (mucopolysaccharidosis type II; MPS II). AVLAYAH is the first FDA-approved biotherapeutic engineered to cross the blood-brain barrier via transferrin receptor-mediated transport, which the company describes as the clinical validation of its proprietary TransportVehicle platform.
The deal and where the money goes
Alexander Schuth, Denali's chief operating and financial officer, said monetising the PRV "strengthens our financial flexibility at a pivotal moment" as the company builds on AVLAYAH's approval. He added that the proceeds would accelerate both the Enzyme TransportVehicle programmes targeting lysosomal storage disorders and the Oligonucleotide and Antibody TransportVehicle programmes aimed at Alzheimer's disease and other neurodegenerative conditions.
Denali's current clinical-stage pipeline spans four named programmes: DNL126 for Sanfilippo syndrome type A, DNL593 for GRN-related frontotemporal dementia, DNL952 for Pompe disease, and DNL628 for Alzheimer's disease. A further four candidates are in IND-enabling studies, covering Alzheimer's, Parkinson's disease, Gaucher disease, Hurler syndrome, and a second Parkinson's target via an oligonucleotide approach.
Market context and competitive landscape
The PRV secondary market has become a meaningful, if volatile, source of non-dilutive capital for biotechs. Vouchers have traded in a wide range historically, from below $100 million to above $350 million; the $195 million figure sits in the mid-range for recent transactions, reflecting a market that has softened somewhat from its 2021 peak. Buyers are typically large pharmaceutical companies seeking to accelerate regulatory review timelines for their own priority assets.
The blood-brain barrier delivery space has attracted significant investment over the past decade, with multiple companies pursuing receptor-mediated transcytosis strategies. Denali's TfR-based approach competes conceptually with antibody-conjugate and lipid nanoparticle platforms being developed by other groups, though Denali holds a first-mover advantage with a now-approved product using this mechanism. That regulatory precedent is commercially significant: it provides a proof-of-concept data package that rivals pursuing similar TfR-targeting mechanisms will need to match or surpass.
For rare lysosomal storage disorder programmes, the regulatory environment in the US remains relatively supportive. The FDA's accelerated approval pathway, which Denali used for AVLAYAH, continues to be available for serious and life-threatening conditions where there is an unmet medical need and a validated surrogate endpoint. Denali will need to confirm clinical benefit in post-approval studies to maintain AVLAYAH's market authorisation, a standard condition of accelerated approval that the company has not yet publicly addressed in detail.
Near-term investor focus will centre on enrolment and data readouts from the DNL126 and DNL952 programmes, which represent the next potential inflection points for the TransportVehicle platform across the lysosomal storage disorder franchise.